Yahoo Finance

Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal ...
Yahoo Finance

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for ...
Business Wire

New Research from IHL Group Shows Retailers’ Cash-handling Costs Range from 4.7% to 15.3%, Depending on Retail Segment

NASHVILLE, Tenn.--(BUSINESS WIRE)--U.S. retailers that are trying to compete with Amazon and Walmart are struggling to find the labor hours to do activities such as Click and Collect, Buy Online ...
Nasdaq

Incannex Healthcare Reports Positive Pharmacokinetic Results for IHL-42X in Obstructive Sleep Apnea Clinical Study

Incannex Healthcare announced positive results from a pharmacokinetics and safety study of IHL-42X, its oral fixed-dose combination of acetazolamide and dronabinol, aimed at treating obstructive sleep ...
Nasdaq

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

NEW YORK and MELBOURNE, Australia, May 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral ...
Business Wire

Retail and Hospitality Research Firm IHL Group Partners With Content Catalyst to Launch New Platform for Data and Research Reports

LEEDS, England--(BUSINESS WIRE)--IHL Group, an advisory and research firm covering the global retail and hospitality sectors, has partnered with technology provider Content Catalyst, to launch an ...